127 related articles for article (PubMed ID: 11755120)
1. Analysis of two matrix metalloproteinase inhibitors and their metabolites for induction of phospholipidosis in rat and human hepatocytes(1).
Gum RJ; Hickman D; Fagerland JA; Heindel MA; Gagne GD; Schmidt JM; Michaelides MR; Davidsen SK; Ulrich RG
Biochem Pharmacol; 2001 Dec; 62(12):1661-73. PubMed ID: 11755120
[TBL] [Abstract][Full Text] [Related]
2. CYP3A induction by N-hydroxyformamide tumor necrosis factor-alpha converting enzyme/matrix metalloproteinase inhibitors use of a pregname X receptor activation assay and primary hepatocyte culture for assessing induction potential in humans.
Tippin TK; Hamilton G; Moore L; Beaudet EJ; Jolley S; Brodie TA; Andrews RC; Becherer JD; McDougald DL; Gaul MD; Hoivik DJ; Mellon-Kusibab K; Lehmann J; Kliewer S; Novick S; Laethem R; Zhao Z; LeCluyse EL
Drug Metab Dispos; 2003 Jul; 31(7):870-7. PubMed ID: 12814963
[TBL] [Abstract][Full Text] [Related]
3. Phospholipidosis assay in HepG2 cells and rat or rhesus hepatocytes using phospholipid probe NBD-PE.
Bhandari N; Figueroa DJ; Lawrence JW; Gerhold DL
Assay Drug Dev Technol; 2008 Jun; 6(3):407-19. PubMed ID: 18537465
[TBL] [Abstract][Full Text] [Related]
4. Use of physicochemical calculation of pKa and CLogP to predict phospholipidosis-inducing potential: a case study with structurally related piperazines.
Ploemen JP; Kelder J; Hafmans T; van de Sandt H; van Burgsteden JA; Saleminki PJ; van Esch E
Exp Toxicol Pathol; 2004 Mar; 55(5):347-55. PubMed ID: 15088636
[TBL] [Abstract][Full Text] [Related]
5. Comparative evaluation of amiodarone-induced phospholipidosis and drug accumulation in Fischer-344 and Sprague-Dawley rats.
Reasor MJ; McCloud CM; Beard TL; Ebert DC; Kacew S; Gardner MF; Aldern KA; Hostetler KY
Toxicology; 1996 Jan; 106(1-3):139-47. PubMed ID: 8571385
[TBL] [Abstract][Full Text] [Related]
6. Cationic amphiphilic drug-induced phospholipidosis.
Halliwell WH
Toxicol Pathol; 1997; 25(1):53-60. PubMed ID: 9061852
[TBL] [Abstract][Full Text] [Related]
7. In vivo and in vitro reversibility of chlorphentermine-induced phospholipidosis in rat alveolar macrophages.
McCloud CM; Beard TL; Kacew S; Reasor MJ
Exp Mol Pathol; 1995 Feb; 62(1):12-21. PubMed ID: 7556587
[TBL] [Abstract][Full Text] [Related]
8. In vitro metabolism of the HIV-1 protease inhibitor ABT-378: species comparison and metabolite identification.
Kumar GN; Jayanti V; Lee RD; Whittern DN; Uchic J; Thomas S; Johnson P; Grabowski B; Sham H; Betebenner D; Kempf DJ; Denissen JF
Drug Metab Dispos; 1999 Jan; 27(1):86-91. PubMed ID: 9884314
[TBL] [Abstract][Full Text] [Related]
9. Imaging Mass Microscopy of Kidneys from Azithromycin-Treated Rats with Phospholipidosis.
Sakurai T; Kamio K; Sasaki K; Nishimoto T; Yamaguchi JI; Sasaki M; Tsutsumi S
Am J Pathol; 2018 Sep; 188(9):1993-2003. PubMed ID: 29981744
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the pharmacology of hydroxamate- and carboxylate-based matrix metalloproteinase inhibitors (MMPIs) for the treatment of osteoarthritis.
Janusz MJ; Hookfin EB; Brown KK; Hsieh LC; Heitmeyer SA; Taiwo YO; Natchus MG; Pikul S; Almstead NG; De B; Peng SX; Baker TR; Patel V
Inflamm Res; 2006 Feb; 55(2):60-5. PubMed ID: 16612565
[TBL] [Abstract][Full Text] [Related]
11. Relationship between in vitro phospholipidosis assay using HepG2 cells and 2-week toxicity studies in rats.
Miyamoto S; Matsumoto A; Mori I; Horinouchi A
Toxicol Mech Methods; 2009 Oct; 19(8):477-85. PubMed ID: 19793005
[TBL] [Abstract][Full Text] [Related]
12. Physicochemical and cell-based approach for early screening of phospholipidosis-inducing potential.
Tomizawa K; Sugano K; Yamada H; Horii I
J Toxicol Sci; 2006 Oct; 31(4):315-24. PubMed ID: 17077586
[TBL] [Abstract][Full Text] [Related]
13. A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system.
Sawada H; Takami K; Asahi S
Toxicol Sci; 2005 Feb; 83(2):282-92. PubMed ID: 15342952
[TBL] [Abstract][Full Text] [Related]
14. Hepatic cells derived from human skin progenitors show a typical phospholipidotic response upon exposure to amiodarone.
Natale A; Boeckmans J; Desmae T; De Boe V; De Kock J; Vanhaecke T; Rogiers V; Rodrigues RM
Toxicol Lett; 2018 Mar; 284():184-194. PubMed ID: 29248575
[TBL] [Abstract][Full Text] [Related]
15. Major phase I biotransformation pathways of Trichostatin a in rat hepatocytes and in rat and human liver microsomes.
Elaut G; Török G; Vinken M; Laus G; Papeleu P; Tourwe D; Rogiers V
Drug Metab Dispos; 2002 Dec; 30(12):1320-8. PubMed ID: 12433798
[TBL] [Abstract][Full Text] [Related]
16. Influence of a pre-existing phospholipidosis on the accumulation of amiodarone and desethylamiodarone in rat alveolar macrophages.
Reasor MJ
Res Commun Chem Pathol Pharmacol; 1991 May; 72(2):169-81. PubMed ID: 1876748
[TBL] [Abstract][Full Text] [Related]
17. Lead-induced phospholipidosis and cholesterogenesis in rat tissues.
Ademuyiwa O; Agarwal R; Chandra R; Behari JR
Chem Biol Interact; 2009 May; 179(2-3):314-20. PubMed ID: 19056365
[TBL] [Abstract][Full Text] [Related]
18. Antidepressant-induced lipidosis with special reference to tricyclic compounds.
Xia Z; Ying G; Hansson AL; Karlsson H; Xie Y; Bergstrand A; DePierre JW; Nässberger L
Prog Neurobiol; 2000 Apr; 60(6):501-12. PubMed ID: 10739086
[TBL] [Abstract][Full Text] [Related]
19. A 96-well flow cytometric screening assay for detecting in vitro phospholipidosis-induction in the drug discovery phase.
Natalie M; Margino S; Erik H; Annelieke P; Geert V; Philippe V
Toxicol In Vitro; 2009 Mar; 23(2):217-26. PubMed ID: 19101623
[TBL] [Abstract][Full Text] [Related]
20. Drug-induced phospholipidosis: are there functional consequences?
Reasor MJ; Kacew S
Exp Biol Med (Maywood); 2001 Oct; 226(9):825-30. PubMed ID: 11568304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
